Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bluebird Bio Inc's Business Segments
Bluebird Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
ZYNTEGLO
Total Revenue
$ 39
Regions Reported
-
Revenue Share by Reportable Segment - FY
- ZYNTEGLO68%
- LYFGENIA32%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| ZYNTEGLO | $ 26 | 68% |
| LYFGENIA | $ 12 | 32% |
Revenue by Product & Service Category - FY
- ZYNTEGLO68%
- LYFGENIA32%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| ZYNTEGLO | $ 26 | 68% |
| LYFGENIA | $ 12 | 32% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- ZYNTEGLO68%
- LYFGENIA32%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| ZYNTEGLO | $ 26 | 68% |
| LYFGENIA | $ 12 | 32% |
Description of Bluebird Bio Inc
Bluebird Bio Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on developing gene therapies for life-threatening diseases. It was founded in 1992 as Genetix Pharmaceuticals and later changed its name to Bluebird Bio in 2010.
Bluebird Bio's main goal is to provide innovative treatments for severe genetic diseases and cancer through the use of gene therapy. The company's approach involves modifying a patient's own cells to introduce functional genes that can correct the underlying genetic mutations causing the disease. This process allows for long-term potential benefits and durable responses.
One of Bluebird Bio's most notable achievements is the development of the first gene therapy approved in Europe, Zynteglo, for patients with transfusion-dependent beta-thalassemia. Zynteglo is designed to treat an inherited blood disorder by introducing a functional gene into the patient's own hematopoietic stem cells, reducing the need for blood transfusions.
Another significant area of focus for Bluebird Bio is the treatment of rare genetic diseases, such as cerebral adrenoleukodystrophy (CALD) and sickle cell disease. The company's investigational gene therapies for these diseases have shown promising results in clinical trials.
Bluebird Bio has also extended its research to include CAR-T cell therapy. This type of therapy involves modifying a patient's own T cells to express chimeric antigen receptors (CARs), which target and kill cancer cells. The company's leading CAR-T cell therapy candidate, idecabtagene vicleucel, is being developed for the treatment of multiple myeloma.
To support its research and development activities, Bluebird Bio has established manufacturing facilities and collaborations with pharmaceutical and academic institutions. The company's manufacturing capabilities include the production of lentiviral vectors, a key component of its gene therapy products.
With a team of dedicated scientists, physicians, and industry experts, Bluebird Bio aims to further advance the field of gene therapy and provide innovative treatment options for patients with life-threatening diseases. The company continues to invest in research, clinical trials, and partnerships to bring novel therapies to the market and improve the lives of those affected by genetic disorders and cancer.
Bluebird Bio's main goal is to provide innovative treatments for severe genetic diseases and cancer through the use of gene therapy. The company's approach involves modifying a patient's own cells to introduce functional genes that can correct the underlying genetic mutations causing the disease. This process allows for long-term potential benefits and durable responses.
One of Bluebird Bio's most notable achievements is the development of the first gene therapy approved in Europe, Zynteglo, for patients with transfusion-dependent beta-thalassemia. Zynteglo is designed to treat an inherited blood disorder by introducing a functional gene into the patient's own hematopoietic stem cells, reducing the need for blood transfusions.
Another significant area of focus for Bluebird Bio is the treatment of rare genetic diseases, such as cerebral adrenoleukodystrophy (CALD) and sickle cell disease. The company's investigational gene therapies for these diseases have shown promising results in clinical trials.
Bluebird Bio has also extended its research to include CAR-T cell therapy. This type of therapy involves modifying a patient's own T cells to express chimeric antigen receptors (CARs), which target and kill cancer cells. The company's leading CAR-T cell therapy candidate, idecabtagene vicleucel, is being developed for the treatment of multiple myeloma.
To support its research and development activities, Bluebird Bio has established manufacturing facilities and collaborations with pharmaceutical and academic institutions. The company's manufacturing capabilities include the production of lentiviral vectors, a key component of its gene therapy products.
With a team of dedicated scientists, physicians, and industry experts, Bluebird Bio aims to further advance the field of gene therapy and provide innovative treatment options for patients with life-threatening diseases. The company continues to invest in research, clinical trials, and partnerships to bring novel therapies to the market and improve the lives of those affected by genetic disorders and cancer.
Bluebird Bio Inc is at the forefront of biotechnology, particularly in the field of gene and cell therapies aimed at addressing severe genetic diseases. Below is an extensive overview of the various segments, products, and services offered by Bluebird Bio Inc:
1. Research and Development (R&D):
- Investment in Innovation: Bluebird Bio Inc dedicates substantial resources to research and development. This investment is oriented toward the discovery and refinement of gene editing technologies and the advancement of gene therapy vectors.
- Understanding Disease Mechanisms: The R&D segment focuses on elucidating the biological underpinnings of severe genetic disorders. This involves a comprehensive study of genetic, molecular, and cellular mechanisms that drive these diseases.
- Clinical Development: R&D encompasses all stages of clinical development, including designing preclinical models, executing Phase I-III clinical trials, and analyzing clinical data. The goal is to gather robust evidence that supports the efficacy and safety of their therapies.
- Collaborative Research: Bluebird Bio often collaborates with academic institutions and research organizations to enhance its R&D capabilities and tap into cutting-edge scientific advancements.
Gene Therapy Products:
- Zynteglo (LentiGlobin): One of Bluebird Bios flagship gene therapy products targeting transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease. Zynteglo introduces a copy of the beta-globin gene to patients hematopoietic stem cells, potentially providing a long-term solution and reducing reliance on blood transfusions.
- Pipeline Expansion: In addition to Zynteglo, Bluebird Bio is actively pursuing other gene therapy candidates aimed at treating diseases like cerebral adrenoleukodystrophy (CALD), and other genetic disorders related to the central nervous system and blood.
- Next-Generation Therapies: The company is exploring novel gene editing techniques such as CRISPR and base editing, which promise higher precision in correcting genetic mutations.
Early-Stage Pipeline:
- Innovative Therapies: The company has a rich early-stage pipeline with investigational gene and cell therapies aimed at various conditions, including neurodegenerative diseases like multiple sclerosis and amyotrophic lateral sclerosis (ALS).
- Diversified Focus: Their pipeline also includes potential treatments for glioblastoma, a particularly aggressive form of brain cancer, and other rare genetic disorders, showcasing Bluebird Bios commitment to addressing a broad spectrum of challenging diseases.
Cell Therapy Products:
- CAR-T Cell Therapies: Beyond gene therapies, Bluebird Bio is engaged in developing cell therapies, specifically Chimeric Antigen Receptor T-cell (CAR-T) therapies. These therapies re-engineer a patients T cells to recognize and attack cancer cells.
- Ide-cel (Abecma): This CAR-T product is in collaboration with Bristol Myers Squibb and targets multiple myeloma. Ide-cel modifies T cells to target the BCMA (B-cell maturation antigen), exhibiting promising efficacy in treating this malignancy.
- Platform Enhancement: Bluebird Bio is also focused on refining CAR-T technology platforms, which involve improving the manufacturing processes, increasing the breadth of applications across various types of cancers, and ensuring safer administration of these therapies.
Commercialization and Patient Support Services:
- Comprehensive Patient Support: Bluebird Bio offers extensive support services for patients undergoing treatment. This includes patient education on the therapies, procedures, and potential side effects.
- Access and Reimbursement Assistance: The company provides services aimed at facilitating therapy access, including assistance with insurance reimbursement processes and navigating healthcare systems to ensure patients receive the required treatments.
- Ongoing Patient Monitoring: Post-treatment, Bluebird Bio finds significance in continued patient monitoring to assess the long-term effectiveness and safety of its therapies. This can include regular follow-ups and collection of health data to improve therapy guidelines over time.
Summary
In summary, Bluebird Bio Inc specializes in gene and cell therapies targeting severe genetic diseases through a robust R&D framework, innovative gene therapy products, diverse early-stage pipeline candidates, advanced CAR-T therapies, and comprehensive patient support services. The company stands at the intersection of cutting-edge science and patient care, dedicating efforts to bring transformative therapies to those in need.
1. Research and Development (R&D):
- Investment in Innovation: Bluebird Bio Inc dedicates substantial resources to research and development. This investment is oriented toward the discovery and refinement of gene editing technologies and the advancement of gene therapy vectors.
- Understanding Disease Mechanisms: The R&D segment focuses on elucidating the biological underpinnings of severe genetic disorders. This involves a comprehensive study of genetic, molecular, and cellular mechanisms that drive these diseases.
- Clinical Development: R&D encompasses all stages of clinical development, including designing preclinical models, executing Phase I-III clinical trials, and analyzing clinical data. The goal is to gather robust evidence that supports the efficacy and safety of their therapies.
- Collaborative Research: Bluebird Bio often collaborates with academic institutions and research organizations to enhance its R&D capabilities and tap into cutting-edge scientific advancements.
Gene Therapy Products:
- Zynteglo (LentiGlobin): One of Bluebird Bios flagship gene therapy products targeting transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease. Zynteglo introduces a copy of the beta-globin gene to patients hematopoietic stem cells, potentially providing a long-term solution and reducing reliance on blood transfusions.
- Pipeline Expansion: In addition to Zynteglo, Bluebird Bio is actively pursuing other gene therapy candidates aimed at treating diseases like cerebral adrenoleukodystrophy (CALD), and other genetic disorders related to the central nervous system and blood.
- Next-Generation Therapies: The company is exploring novel gene editing techniques such as CRISPR and base editing, which promise higher precision in correcting genetic mutations.
Early-Stage Pipeline:
- Innovative Therapies: The company has a rich early-stage pipeline with investigational gene and cell therapies aimed at various conditions, including neurodegenerative diseases like multiple sclerosis and amyotrophic lateral sclerosis (ALS).
- Diversified Focus: Their pipeline also includes potential treatments for glioblastoma, a particularly aggressive form of brain cancer, and other rare genetic disorders, showcasing Bluebird Bios commitment to addressing a broad spectrum of challenging diseases.
Cell Therapy Products:
- CAR-T Cell Therapies: Beyond gene therapies, Bluebird Bio is engaged in developing cell therapies, specifically Chimeric Antigen Receptor T-cell (CAR-T) therapies. These therapies re-engineer a patients T cells to recognize and attack cancer cells.
- Ide-cel (Abecma): This CAR-T product is in collaboration with Bristol Myers Squibb and targets multiple myeloma. Ide-cel modifies T cells to target the BCMA (B-cell maturation antigen), exhibiting promising efficacy in treating this malignancy.
- Platform Enhancement: Bluebird Bio is also focused on refining CAR-T technology platforms, which involve improving the manufacturing processes, increasing the breadth of applications across various types of cancers, and ensuring safer administration of these therapies.
Commercialization and Patient Support Services:
- Comprehensive Patient Support: Bluebird Bio offers extensive support services for patients undergoing treatment. This includes patient education on the therapies, procedures, and potential side effects.
- Access and Reimbursement Assistance: The company provides services aimed at facilitating therapy access, including assistance with insurance reimbursement processes and navigating healthcare systems to ensure patients receive the required treatments.
- Ongoing Patient Monitoring: Post-treatment, Bluebird Bio finds significance in continued patient monitoring to assess the long-term effectiveness and safety of its therapies. This can include regular follow-ups and collection of health data to improve therapy guidelines over time.
Summary
In summary, Bluebird Bio Inc specializes in gene and cell therapies targeting severe genetic diseases through a robust R&D framework, innovative gene therapy products, diverse early-stage pipeline candidates, advanced CAR-T therapies, and comprehensive patient support services. The company stands at the intersection of cutting-edge science and patient care, dedicating efforts to bring transformative therapies to those in need.